Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
about
Dopamine release in the basal gangliaVarenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatumAlpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's diseaseStriatal dopamine neurotransmission: regulation of release and uptakeFocus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damageCotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatumα6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Nicotine and Parkinson's disease: implications for therapy.Native α6β4* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland.Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbensα6 nAChR subunit residues that confer α-conotoxin BuIA selectivityα7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.Unfolding the fold of cyclic cysteine-rich peptides.Nicotinic receptors as CNS targets for Parkinson's diseaseNicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmissionPositional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum.Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.Amino acid residues that confer high selectivity of the alpha6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A,E11A,L15A].Probing striatal microcircuitry to understand the functional role of cholinergic interneurons.Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and functionMultiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.Neuronal Nicotinic Acetylcholine Receptor Modulators from Cone Snails.
P2860
Q22251247-7A8BF2B1-A9E3-4844-8AD2-F16580C7448BQ28576280-9A6AF0BC-3B47-45A6-98CC-524461B3470AQ33621205-A8AD96D4-49C2-41AB-9B80-BCDD8B953169Q33954007-D3F79F8C-632C-40A6-A1FD-CD7C53CFBDADQ34048086-5C7884F9-F7E2-46A9-9E3F-235EE2417FB5Q34112026-6D85DEDF-DBAF-49DF-BF97-0C343F574FAAQ34309950-2B53E94B-CE31-4EA7-B4F3-EF075073B7B1Q34524803-A4FE36F3-BDE5-4FA0-8FDE-44E715CC01DFQ34793270-2E008CF8-0F4A-44FC-B441-957F28268A9BQ35097046-1E6F0636-3EE8-46E0-B8E0-6B7A4527A28EQ35098275-2B49A136-D1AF-43C8-BAAA-E3C02E235C95Q35098752-1FB91A83-A642-4D3C-AB00-A9A252FA010FQ35264378-53D2A4AF-4CC2-452F-8FB1-475E17997E4CQ35601652-B9365010-DCEB-4821-B5DC-8831D29D1376Q35648038-6B5261A5-7482-4122-806D-8451428D339FQ35690145-C319B40B-EB91-4564-B42A-2FAD6680C9B5Q35974049-18BDEDAC-A2F8-4A24-BF53-6C5B2B367338Q36105359-46E063DC-BD0B-4DD2-9E3A-4123C4DBECBBQ36252353-38EBA723-0EC3-4CEB-AB9A-8B4E3EEEB28DQ36469995-FEF43218-F6EA-45F8-94F4-35BD68F3CEC8Q36470454-7886D828-AE2E-4A30-BAED-1C3E940EE3C2Q36882136-CF5B5819-7F83-43A7-ACEC-4ABEBB3485E4Q36936920-E360C3C2-3FD0-4174-96E1-0570443FBBEAQ36936930-395AC9FB-47F2-4E5E-9FFE-F1A5F7036199Q37014100-652C3E58-FF69-4557-AA6D-E3B595572C1EQ37132142-A97AC8A9-9C24-455E-96D5-D908CD6CF39CQ37132559-74722256-068B-4A7D-AFF4-149A3FE9E982Q37180827-F7A66ECF-2ED7-46BF-AA1F-221F62280AD3Q37384621-373436A1-5D40-41F2-AE91-8B15B5D7D7B5Q37508589-9607DBDC-1A6B-4AB0-B33C-8BBA0C783816Q37708588-99AB5667-8B2C-4BDB-83B2-72C78C25C252Q38293240-3DFDAB43-F21A-4B7B-955F-9A8D703BD812Q38557880-1C530B9C-3F64-4D6C-8D5F-F8958A758DE0Q39850502-CF4818E2-19D5-4A68-8C42-5CF3AC8317EDQ42676936-3649528A-19E2-4C05-8213-D5D5929350B4Q55515324-48915C83-6029-4C4A-8AD8-64FDAB19DC13
P2860
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@en
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@nl
type
label
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@en
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@nl
prefLabel
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@en
Vulnerability of 125I-alpha-co ...... igrostriatal damage in monkey.
@nl
P2093
P1476
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey
@en
P2093
J M McIntosh
Y Polonskaya
P304
P356
10.1523/JNEUROSCI.21-15-05494.2001
P407
P577
2001-08-01T00:00:00Z